| Similar Articles |
|---|
 |
The Motley Fool
October 30, 2006
Brian Lawler |
Vertex's Healthy Trial Results Shares of the pharmaceutical company were up on the release of positive clinical trial data.   |
Chemistry World
December 9, 2009
Sarah Houlton |
New hep C breakthrough A drug being developed by Denmark's Santaris Pharma could provide a breakthrough in the treatment of hepatitis C, and positive results in a study on chimpanzees point to its potential to avoid drug resistance. |
The Motley Fool
May 27, 2005
Charly Travers |
Vertex's Cautious Optimism The company's innovative hepatitis C drug has made May a month to remember. Investors, take note. |
Nurse Practitioner
December 2009
Gujral & Collantes |
Understanding Viral Hepatitis: A guide for primary care Recent advancements in the field of genomics and proteomics technology have given researchers and clinicians more insight on disease pathogenesis and helped create more tailored approaches to the treatment of these conditions. |
The Motley Fool
April 19, 2005
Charly Travers |
A Rising Star in Biotech Idenix is following a proven path to success: novel drug development. This is one biotech to keep on your watch list for the next year. |
American Family Physician
March 15, 2004 |
Hepatitis C What is hepatitis C? How is it spread? |
The Motley Fool
April 27, 2005
Charly Travers |
Vertex's Emerging Pipeline Early-stage drugs, including one for hepatitis C, are moving forward. For Vertex investors, the phase 2 trials will be the story to watch over the next two years. |
The Motley Fool
September 28, 2007
Brian Orelli |
Idenix Axes Ailing Initiatives The small drug developer drops its hepatitis B program, deciding instead to focus on its HCV and HIV drug development. Investors, take note. |
Chemistry World
January 11, 2012
Andrew Turley |
BMS spends $2.5 billion on antiviral firm The move will stock Bristol-Myers Squibb's pipeline with antivirals, most notably INX-189, a nucleotide polymerase inhibitor which is in Phase II trials for treating hepatitis C virus infection. |
The Motley Fool
February 10, 2005
Charly Travers |
Focus on the Pipeline Vertex Pharmaceuticals is losing money. But it has at least one drug that makes the future look brighter. |
The Motley Fool
February 26, 2010
Brian Orelli |
A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus. |
Chemistry World
June 12, 2014
Philli Broadwith |
Merck & Co bolsters hepatitis C pipeline with Idenix acquisition US drug firm Merck & Co has agreed to buy hepatitis C specialist Idenix for $3.85 billion. |
The Motley Fool
October 19, 2007
Brian Lawler |
Schering's Gain Is Only a Mild Headache for Vertex Schering-Plough's strong phase 2 clinical results of its hepatitis C virus drug candidate send shares of competitor Vertex down. |
BusinessWeek
November 29, 2004
Kerry Capell |
"A Vaccine Every Woman Should Take" Two drug companies are closing in on shots against HPV, the leading cause of cervical cancer. Despite the obvious benefits, the vaccines may not be an easy sell: There are social and moral hurdles to overcome. |
The Motley Fool
October 26, 2007
Brian Lawler |
Another Prospect for Flamel The drug developer's good week continues with favorable news about a treatment for hepatitis C. Investors, take note. |
Chemistry World
February 4, 2009
Matt Wilkinson |
GSK targets autoimmune biologics GSK recently signed seven drug development deals that could see the company release a suite of drugs to treat inflammatory diseases ranging from rheumatoid arthritis to lupus. |
The Motley Fool
September 11, 2007
Brian Lawler |
Score One for Pharmasset Shares of Pharmasset were up after the company announced impressive results for its Hepatitis C virus drug candidate R7128. Investors should continue to watch closely. |
Chemistry World
April 21, 2010
Sarah Houlton |
Fresh hep C hope A new kind of compound to treat hepatitis C is showing promise in early clinical trials. |
The Motley Fool
August 10, 2010
Ryan McBride |
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive. |
The Motley Fool
September 27, 2007
Brian Lawler |
ViroPharma's Good Bad News The prospects for ViroPharma's HCV-796 darkened significantly after the company reported troubling clinical results, however, there's still hope for the compound. Investors, take note. |
The Motley Fool
October 31, 2007
Brian Lawler |
The Next Hepatitis C Blockbuster? Never before have there been so many new drugs in development to treat Hepatitis C. Which companies have the compounds most likely to win this race? Investors, take note. |
Chemistry World
October 1, 2014
Phillip Broadwith |
J&J to buy antiviral specialist Alios Johnson and Johnson has agreed to buy antiviral specialist Alios BioPharma for $1.75 billion |
The Motley Fool
April 29, 2008
Brian Lawler |
So Pharmasset, So Good Early data hints at a promising hepatitis C treatment. |
The Motley Fool
December 28, 2007
Brian Lawler |
Cubist's Cheap Call Option As a Christmas Eve present to itself, Cubist Pharmaceuticals follows through on its October option to purchase Illumigen. |
The Motley Fool
March 20, 2008
Brian Lawler |
Gilead Not Slowing Gilead Sciences gets a new approval for a drug. |
Chemistry World
April 25, 2014
Andy Extance |
$25bn-plus trade sharpens pharma giants' focus Three leading pharmaceutical firms are set to exchange business segments valued at over $25 billion, in deals affecting at least 14,000 employees. |
Chemistry World
December 3, 2013
Phillip Broadwith |
New wave of hepatitis C drugs hits US shore Johnson & Johnson's hepatitis C drug Olysio (simeprevir) has been approved by the US Food and Drug Administration. |
The Motley Fool
May 19, 2010
Brian Orelli |
The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd. |
The Motley Fool
September 7, 2010
Luke Timmerman |
ZymoGenetics, Seattle Biotech Pioneer, Acquired by Bristol-Myers for $885 Million The two companies have gotten to know each other quite well since January 2009, when Bristol agreed to pay as much as $1.1 billion for the right to co-develop and co-market a drug for hepatitis C. |
The Motley Fool
December 14, 2006
Brian Lawler |
Vertex: Coming Together Nicely If telaprevir continues to show anything like the 80%-90% rate of undetectable hepatitis C virus at end of its trials, Vertex shareholders won't be dealing with too many more down days. |
The Motley Fool
April 30, 2008
Brian Lawler |
Idenix Aims for a Comeback This drugmaker may be down, but it's not yet out. |
The Motley Fool
May 17, 2011
Luke Timmerman |
Merck, Genentech Team Up on Hepatitis C Drug Merck pulling lots of strings to grab market share against Vertex. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Hepatitis C: Another Protease Revolution The launch of a new class of protease inhibitors is set to transform HCV treatment over the next decade, with kinder, gentler oral antiviral cocktails that will increase success rates from 50 percent to 75 percent. |
The Motley Fool
April 3, 2008
Brian Lawler |
Will InterMune's Hepatitis C Drug Compete? InterMune announces positive data for its hepatitis C treatment drug. |
The Motley Fool
October 5, 2010
Brian Orelli |
You Should Have Seen this FDA Rejection Coming This hepatitis C treatment was marked for failure. |
The Motley Fool
November 8, 2007
Brian Lawler |
Idenix Reels Itself In The small-cap drug developer cuts expenditures in the third quarter when sales of their hepatitis treatment don't materialize as quickly as hoped. Investors, take note. |
The Motley Fool
June 15, 2007
Brian Lawler |
Idenix Gets Knocked Shares of Idenix drop slightly after the drug developer released clinical trial results this week. |
The Motley Fool
November 6, 2007
Brian Lawler |
No Surprise That Vertex Has Competition Did shares of Vertex Pharmaceuticals slump on competition concerns? |
Chemistry World
August 20, 2009
Sarah Houlton |
Testing times: predicting hep C response A finding by David Goldstein and his group at Duke University in the US may make it possible to predict which patients are likely to benefit from the drugs, and which will probably suffer the nasty side-effects without much chance of success. |
BusinessWeek
April 26, 2004
Kerry Capell |
Vaccinating The World's Poor GlaxoSmithKline Biologicals is betting it can combat Third World scourges -- and still make money. |
The Motley Fool
March 27, 2007 |
Fast Pitch: Vertex Pharmaceuticals 2007 is expected to be a very eventful year for the pharmaceutical, as it will furnish some important clinical trial results for its investigational drugs. Investors, take note. |
Chemistry World
July 25, 2008
Sarah Houlton |
Small is beautiful for GSK drug discovery New GlaxoSmithKline chief executive Andrew Witty is restructuring the firm's drug discovery, setting up small, highly focussed research teams that will have to bid for funding. |
Nursing
December 2008
Susan Simmons Holcomb |
Caring for a patient with chronic hepatitis C Teach your patient about improved treatments that can help him deal with this potentially deadly infection. |
The Motley Fool
April 19, 2004
Charly Travers |
4 Promising Biotech IPOs Several recently gone-public biotechs boast surprisingly interesting drug pipelines. From drugs for hepatitis to hopeful cancer treatments, watch out for these four biotech debutantes. If trials go smoothly, they may be the next up-and-coming stocks in the industry. |
The Motley Fool
January 8, 2008
Brian Lawler |
InterMune Goes Step by Step The company updates investors on the progress of its lead drug for hepatitis C. |
The Motley Fool
May 28, 2010
Brian Orelli |
Innovators Will Rule the Economic Crisis Roche's CEO says two areas of health care can prosper. I agree. |
The Motley Fool
April 17, 2008
Brian Lawler |
The End for (Another) Hepatitis C Drug Candidate ViroPharma stops development of its compound after data showed it may hurt the liver. |
Chemistry World
April 20, 2009
Phil Taylor |
GSK and Pfizer join forces in fight against HIV The world's two biggest pharmaceutical companies, GlaxoSmithKline (GSK) and Pfizer, are bundling their HIV activities into a joint venture company in a move they claim is both 'unique and innovative'. |
American Family Physician
January 1, 2004
Lin & Kirchner |
Hepatitis B Hepatitis B causes significant morbidity and mortality worldwide. Effective vaccines for hepatitis B virus have been available since 1982; infant and childhood vaccination programs introduced in the 1990s have resulted in a marked decrease in new infections. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA |
